Trials Sponsors Conditions Drugs Pricing

Conditions

Carotid Artery Stenosis Stroke TIA

Keywords

White Matter HyperintensityStrokeCarotid Artery Plaque InflammationFDG PETMRITIA

Outcome Measures

Primary Outcomes (1)

Plaque Inflammation
The extent to which plaque inflammation, as measured by the extent of FDG uptake, contributes to the number of covert infarcts and the magnitude of white matter hyperintensity.
30 days

Study Arms (1)

Nuclear imaging

EXPERIMENTAL

PET/CT imaging with F-18 fluorodeoxyglucose

Radiation: PET/CT imaging with F-18 fluorodeoxyglucose

Interventions

PET/CT imaging with F-18 fluorodeoxyglucoseRadiation

Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.

Nuclear imaging

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age60 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age 60 or greater at time of enrollment
Written informed consent from patient or legal representative

Sponsors & Collaborators

The Ottawa Hospital
Othercollaborator
Ottawa Heart Institute Research Corporation
Otherlead

Study Sites (1)

The Ottawa Hospital, Civic Campus

Ottawa, Ontario, K1Y 4E9, Canada

MeSH Terms

Conditions

StrokeCarotid Stenosis

Interventions

Fluorodeoxyglucose F18

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesCarotid Artery DiseasesArterial Occlusive Diseases

Intervention Hierarchy (Ancestors)

DeoxyglucoseDeoxy Sugars

Study Officials

Terrence Ruddy, MD
The Ottawa Hospital
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NA
Masking: NONE
Purpose: SCREENING
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

November 5, 2010

First Posted

November 8, 2010

Study Start

November 2010

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

October 27, 2016

Study Stopped

Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Nuclear imaging

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Nuclear imaging

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations